Needham Maintains Buy on CRISPR Therapeutics, Raises Price Target to $88
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Gil Blum has reaffirmed a Buy rating on CRISPR Therapeutics (NASDAQ:CRSP) and increased the price target from $85 to $88.
December 11, 2023 | 9:30 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Needham analyst Gil Blum maintains a Buy rating on CRISPR Therapeutics and raises the price target from $85 to $88, indicating a positive outlook on the stock.
The increase in price target by a reputable analyst suggests a positive outlook on CRISPR Therapeutics' stock, which could lead to increased investor confidence and a potential short-term rise in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100